KCA
TNGX icon

KVP Capital Advisors’s Tango Therapeutics TNGX Stock Holding History

KVP Capital Advisors’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.2M Hold
230,264
– – 5.28% 6
2026
Q1 		$4.82M Buy
+230,264
New +$3.2M 3.6% 9

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

KVP Capital Advisors's TNGX Position: Q2 2026 in Review

KVP Capital Advisors held its Tango Therapeutics (TNGX) position steady in Q2 2026 at 230,264 shares worth $7.2M. The position accounts for 5.28% of the portfolio, ranked #6.

KVP Capital Advisors first reported a position in TNGX in Q1 2026 and has held it in 2 quarters since. 247 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • KVP Capital Advisors held 230,264 shares of Tango Therapeutics worth $7.2M as of Q2 2026.
  • KVP Capital Advisors left its Tango Therapeutics share count unchanged in Q2 2026.
  • Tango Therapeutics made up 5.28% of KVP Capital Advisors's portfolio in Q2 2026, its #6 holding.
  • KVP Capital Advisors first reported a position in Tango Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 247 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on KVP Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.